Since high DCLK1 expression in pancreatic cancer patients is correlated with activation of pathways downstream of RAS (PI3K/MTOR) (Figure 3), we also assessed the effect of overexpressing DCLK1-AL on Everolimus (MTOR inhibitor), LY-294002 (PI3K inhibitor), and ABT-199 (BCL-2 inhibitor) treated pancreatic cancer cells. Here, BCL2 is linked to familial pancreatic carcinoma.